Dementia
Disease State Hub
Featured
05/01/2026
Anthony Calabro, MA
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
05/01/2026
04/01/2026
In this podcast, Ruth Frikke-Schmidt, MD, DMSc, examines whether elevated BMI causally increases the risk of vascular dementia and how blood pressure and metabolic factors may mediate this association,...
04/01/2026
01/06/2026
Kate Young
Throughout this winter season our editorial team has brought you timely, evidence-based coverage that spanned clinical research, practice challenges, expert insights, and interactive learning. In this...
01/06/2026
Interactive Features
01/06/2026
Kate Young
Throughout this winter season our editorial team has brought you timely, evidence-based coverage that spanned clinical research, practice challenges, expert insights, and interactive learning. In this...
01/06/2026
02/22/2024
In their presentation at the Practical Updates in Primary Care 2023 Virtual Series, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C reviewed the pathophysiological mechanisms of agitation...
02/22/2024
12/02/2023
Your patient is a 46-year-old woman with a family history of dementia and obesity. Based on her family history, she asks you if there is a way to reduce her risk of developing dementia, and a way to stay...
12/02/2023
11/11/2023
Increasing age is a risk factor for Alzheimer dementia (AD), and as the US population grows older and lives longer, new and existing cases of AD are projected to rise as well. How many older Americans are...
11/11/2023
04/16/2023
Your patient is a 56-year-old woman with a family history of dementia. She asks you if her coffee intake would increase her risk of being diagnosed with dementia in the future.
04/16/2023
Clinical Insights
09/11/2025
Kasia Rothenberg, MD, PhD
In this video, Kasia Rothenberg, MD, PhD, describes Alzheimer disease-related agitation, details the difficulty in testing for Alzheimer disease-related agitation, looks ahead to potential treatment options...
09/11/2025
11/20/2024
Gautam Dantas, PhD
In this video, Gautam Dantas, PhD, discusses the results of his study, which showed that altered gut bacteria may be an indicator of the earliest stages of Alzheimer disease. He also talks about whether...
11/20/2024
04/19/2024
In this video, Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C provide the take-home messages from their session “Agitation in Alzheimer’s Dementia: Progress for an Age-Old Problem” at our...
04/19/2024
04/14/2024
Samar R. El Khoudary, PhD, MPH, BPharm, FAHA
In a long-term follow-up study, Samar R. El Khoudary, PhD, MPH, BPharm, FAHA, and colleagues investigated how the quantity and quality of cardiovascular fat in women with Alzheimer disease measured during...
04/14/2024
03/25/2024
Brenden P. Lucy, MD
In a small clinical trial, researchers found that patients taking suvorexant, an FDA-approved treatment for insomnia, had reduced levels of amyloid beta (amyloid-β) and tau phosphorylation proteins, which...
03/25/2024
